Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rani Therapeutics Holdings (RANI) Tax Provisions (2020 - 2022)

Rani Therapeutics Holdings has reported Tax Provisions over the past 3 years, most recently at -$11000.0 for Q4 2022.

  • Quarterly results put Tax Provisions at -$11000.0 for Q4 2022, up 72.5% from a year ago — trailing twelve months through Dec 2023 was -$11000.0 (down 111.0% YoY), and the annual figure for FY2022 was $100000.0, up 143.9%.
  • Tax Provisions for Q4 2022 was -$11000.0 at Rani Therapeutics Holdings, up from -$106000.0 in the prior quarter.
  • Over the last five years, Tax Provisions for RANI hit a ceiling of $154000.0 in Q2 2022 and a floor of -$106000.0 in Q3 2022.
  • Median Tax Provisions over the past 3 years was $6000.0 (2020), compared with a mean of $14909.1.
  • Biggest five-year swings in Tax Provisions: crashed 433.33% in 2021 and later skyrocketed 15300.0% in 2022.
  • Rani Therapeutics Holdings' Tax Provisions stood at $12000.0 in 2020, then crashed by 433.33% to -$40000.0 in 2021, then surged by 72.5% to -$11000.0 in 2022.
  • The last three reported values for Tax Provisions were -$11000.0 (Q4 2022), -$106000.0 (Q3 2022), and $154000.0 (Q2 2022) per Business Quant data.